• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's Intraday Session

    10/16/23 1:31:09 PM ET
    $ALDX
    $AMAM
    $BIOC
    $MODD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ALDX alert in real time by email

    Gainers

    • Tempest Therapeutics (NASDAQ:TPST) shares increased by 94.8% to $7.09 during Monday's regular session. Tempest Therapeutics's stock is trading at a volume of 107.5 million shares as of 13:30 EST. This is 2416.7% of its average full-day volume over the last 100 days. The company's market cap stands at $94.4 million.
    • Redhill Biopharma (NASDAQ:RDHL) shares rose 34.43% to $0.43. Trading volume for Redhill Biopharma's stock is 15.2 million as of 13:30 EST. This is 1823.6% of its average full-day volume over the last 100 days. The company's market cap stands at $2.5 million.
    • Processa Pharma (NASDAQ:PCSA) stock increased by 31.45% to $0.63. As of 13:30 EST, this security is trading at a volume of 64.8 million shares, making up 16575.5% of its average full-day volume over the last 100 days. The company's market cap stands at $15.5 million.
    • Mereo BioPharma Group (NASDAQ:MREO) stock rose 30.19% to $1.68. As of 13:30 EST, this security is trading at a volume of 17.1 million shares, making up 2011.2% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $235.5 million.
    • Rani Therapeutics Hldgs (NASDAQ:RANI) stock rose 23.73% to $2.45. Trading volume for Rani Therapeutics Hldgs's stock is 140.7K as of 13:30 EST. This is 325.4% of its average full-day volume over the last 100 days. The company's market cap stands at $62.5 million.
    • Modular Medical (NASDAQ:MODD) shares rose 22.82% to $1.13. The company's market cap stands at $23.8 million.

    Losers

    • Streamline Health Solns (NASDAQ:STRM) shares declined by 67.0% to $0.24 during Monday's regular session. As of 13:30 EST, this security is trading at a volume of 2.6 million shares, making up 2236.8% of its average full-day volume over the last 100 days. The company's market cap stands at $14.3 million.
    • Aldeyra Therapeutics (NASDAQ:ALDX) shares declined by 66.12% to $1.84. As of 13:30 EST, this security is trading at a volume of 18.5 million shares, making up 3344.6% of its average full-day volume over the last 100 days. The company's market cap stands at $107.8 million.
    • Biocept (NASDAQ:BIOC) shares fell 49.03% to $0.52. Biocept's stock is trading at a volume of 1.3 million shares as of 13:30 EST. This is 73.6% of its average full-day volume over the last 100 days. The company's market cap stands at $1.3 million.
    • Ambrx Biopharma (NASDAQ:AMAM) stock declined by 30.75% to $9.73. Trading volume for this security as of 13:30 EST is 6.7 million, which is 1516.3% of its average full-day volume over the last 100 days.
    • Omeros (NASDAQ:OMER) stock decreased by 30.4% to $1.58. Trading volume for Omeros's stock is 6.1 million as of 13:30 EST. This is 1368.9% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $99.3 million.
    • Nexalin Technology (NASDAQ:NXL) shares declined by 27.6% to $0.34. The current volume of 801.7K shares is 3475.6% of Nexalin Technology's average full-day volume over the last 100 days (last updated at 13:30 EST). The market value of their outstanding shares is at $2.4 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ALDX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALDX
    $AMAM
    $BIOC
    $MODD

    CompanyDatePrice TargetRatingAnalyst
    Rani Therapeutics Holdings Inc.
    $RANI
    4/14/2026$9.00Buy
    Lake Street
    Mereo BioPharma Group plc
    $MREO
    3/23/2026Overweight → Neutral
    Analyst
    Aldeyra Therapeutics Inc.
    $ALDX
    3/18/2026$2.00Buy → Neutral
    H.C. Wainwright
    Tempest Therapeutics Inc.
    $TPST
    1/22/2026$11.00Neutral → Buy
    H.C. Wainwright
    Mereo BioPharma Group plc
    $MREO
    12/30/2025$0.50Buy → Hold
    Jefferies
    Omeros Corporation
    $OMER
    6/10/2025$9.00Buy
    H.C. Wainwright
    Tempest Therapeutics Inc.
    $TPST
    4/10/2025Sector Outperform → Sector Perform
    Scotiabank
    Tempest Therapeutics Inc.
    $TPST
    4/10/2025Buy → Neutral
    H.C. Wainwright
    More analyst ratings

    $ALDX
    $AMAM
    $BIOC
    $MODD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Raday Gilead

    4 - RedHill Biopharma Ltd. (0001553846) (Issuer)

    4/22/26 6:09:14 PM ET
    $RDHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Young David

    4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)

    4/17/26 4:55:16 PM ET
    $PCSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Ng George K

    4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)

    4/17/26 4:54:02 PM ET
    $PCSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALDX
    $AMAM
    $BIOC
    $MODD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026

    New preclinical data, independently presented in two posters at the 2026 American Association for Cancer Research (AACR) Annual Meeting, show positive effects of opaganib[1] as potential add-on therapy in models of neuroblastoma (NB) and triple-negative breast cancer (TNBC)The positive NB data from studies undertaken by Penn State University's Jeremy Hengst and Apogee Biotechnology, and funded by the Beat Childhood Cancer Foundation and Four Diamonds, indicate that opaganib may enhance the therapeutic efficacy of the oxaliplatin + doxorubicin (OXDOX) chemotherapy combination in high-risk NB by directly destabilizing n-Myc, a key oncogenic driver of neuroblastoma and other solid tumors, throu

    4/22/26 8:00:00 AM ET
    $CPIX
    $RDHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T

    Delivery of TPST-2003 lentiviral vector to Cincinnati Children's Applied Gene and Cell Therapy Center enables manufacturing activities required for pivotal developmentTech transfer on track to support initiation of potentially registrational study in Q4 2026Key manufacturing milestone follows Tempest's recent announcement of positive interim data from the ongoing REDEEM-1 Phase 1/2a trial of TPST-2003, including 100% complete response in all six efficacy evaluable patients, and accelerated development timeline BRISBANE, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST) ("Tempest"), a clinical-stage biotechnology company developing a pipeline of advanced C

    4/22/26 8:00:00 AM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sagimet Biosciences Announces Appointment of Andreas Grauer, MD, as Chief Medical Officer

    SAN MATEO, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced the appointment of Andreas Grauer, MD, as Chief Medical Officer, effective April 20, 2026. Sagimet's prior Chief Medical Officer, Eduardo Bruno Martins, MD, DPhil, who will continue to support the Company as an external scientific advisor, has retired effective April 20, 2026. "We are delighted to welcome Dr. Andreas Grauer to our executive leadership team as Chief Medical Officer. Dr. Grauer has an extensive track record in leading clinical development

    4/20/26 7:00:00 AM ET
    $OMER
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALDX
    $AMAM
    $BIOC
    $MODD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Imran Mir A bought $1,260,417 worth of shares (2,083,334 units at $0.60) (SEC Form 4)

    4 - Rani Therapeutics Holdings, Inc. (0001856725) (Issuer)

    10/27/25 7:24:25 PM ET
    $RANI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Principal Financial Officer Alfieri Michael bought $13,250 worth of shares (2,500 units at $5.30) (SEC Form 4)

    4 - Aldeyra Therapeutics, Inc. (0001341235) (Issuer)

    8/15/25 4:09:59 PM ET
    $ALDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Manchester Management Co Llc bought $1,299,997 worth of shares (677,082 units at $1.92) (SEC Form 4)

    4 - Modular Medical, Inc. (0001074871) (Issuer)

    3/24/25 9:34:00 PM ET
    $MODD
    Medical/Dental Instruments
    Health Care

    $ALDX
    $AMAM
    $BIOC
    $MODD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lake Street initiated coverage on Rani Therapeutics with a new price target

    Lake Street initiated coverage of Rani Therapeutics with a rating of Buy and set a new price target of $9.00

    4/14/26 9:27:33 AM ET
    $RANI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mereo BioPharma downgraded by Analyst

    Analyst downgraded Mereo BioPharma from Overweight to Neutral

    3/23/26 8:27:06 AM ET
    $MREO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aldeyra Therapeutics downgraded by H.C. Wainwright with a new price target

    H.C. Wainwright downgraded Aldeyra Therapeutics from Buy to Neutral and set a new price target of $2.00

    3/18/26 8:20:05 AM ET
    $ALDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALDX
    $AMAM
    $BIOC
    $MODD
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Omeros Corporation

    SCHEDULE 13G/A - OMEROS CORP (0001285819) (Subject)

    4/23/26 10:08:39 AM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-3 filed by Modular Medical Inc.

    S-3 - Modular Medical, Inc. (0001074871) (Filer)

    4/23/26 8:00:56 AM ET
    $MODD
    Medical/Dental Instruments
    Health Care

    Nexalin Technology Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Nexalin Technology, Inc. (0001527352) (Filer)

    4/22/26 4:30:18 PM ET
    $NXL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ALDX
    $AMAM
    $BIOC
    $MODD
    Financials

    Live finance-specific insights

    View All

    Join Nexalin's Exclusive Live Investor Webinar and Q&A Session on April 21

    ORLANDO, FL, April 14, 2026 (GLOBE NEWSWIRE) -- RedChip Companies will host an investor webinar on April 21, 2026, at 4:15 p.m. ET with Nexalin Technology, Inc. (NASDAQ:NXL, NXLIW)). The exclusive event will feature Nexalin's CEO Mark White, who will provide an in-depth overview of the company's differentiated approach to mental healthcare through its proprietary, non-invasive Deep Intracranial Frequency Stimulation (DIFS™) technology. White will highlight Nexalin's expanding body of clinical evidence—including peer-reviewed studies and collaborations with leading institutions such as UC San Diego—while outlining progress across its next-generation product portfolio, including the Gen-3 H

    4/14/26 8:30:00 AM ET
    $NXL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Omeros Corporation Reports Fourth Quarter and Year-End 2025 Financial Results

    – Conference Call Today at 4:30 p.m. ET Omeros Corporation (NASDAQ:OMER) today announced recent highlights and developments as well as financial results for the fourth quarter and year ended December 31, 2025, which include: Net income for the fourth quarter of 2025 was $86.5 million, or $1.22 per share, compared to a net loss of $31.4 million, or $0.54 per share, for the fourth quarter of 2024. For the year ended December 31, 2025, net loss was $3.4 million, or $0.05 per share, compared to a net loss of $156.8 million, or $2.70 per share, in the prior year. Fourth quarter results include a net gain of $237.6 million tied to the zaltenibart transaction with Novo Nordisk. The fourth

    3/31/26 4:02:00 PM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate Update

    - Announced up to $1.085 billion collaboration with Chugai Pharmaceutical Co. for multiple high-value therapeutics and completed $60.3 million oversubscribed private placement led by Samsara BioCapital with participation from RA Capital Management, Special Situations Funds, and Invus – - Announced preclinical data demonstrating successful oral delivery of semaglutide via RaniPill® – - Announced preclinical data demonstrating the bioequivalence of RT-114, a bispecific GLP-1/GLP-2 dual agonist (PG-102) delivered orally via the RaniPill® capsule, to subcutaneous administration of PG-102 – - Initiated Phase 1 Study of RT-114 RaniPill® for the treatment of obesity in collaboration with ProGen

    3/26/26 4:05:00 PM ET
    $RANI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALDX
    $AMAM
    $BIOC
    $MODD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Modular Medical Inc.

    SC 13D/A - Modular Medical, Inc. (0001074871) (Subject)

    11/25/24 7:18:33 PM ET
    $MODD
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Aldeyra Therapeutics Inc.

    SC 13G/A - Aldeyra Therapeutics, Inc. (0001341235) (Subject)

    11/14/24 4:50:29 PM ET
    $ALDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Mereo BioPharma Group plc

    SC 13G/A - Mereo BioPharma Group plc (0001719714) (Subject)

    11/14/24 4:18:45 PM ET
    $MREO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALDX
    $AMAM
    $BIOC
    $MODD
    Leadership Updates

    Live Leadership Updates

    View All

    Sagimet Biosciences Announces Appointment of Andreas Grauer, MD, as Chief Medical Officer

    SAN MATEO, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced the appointment of Andreas Grauer, MD, as Chief Medical Officer, effective April 20, 2026. Sagimet's prior Chief Medical Officer, Eduardo Bruno Martins, MD, DPhil, who will continue to support the Company as an external scientific advisor, has retired effective April 20, 2026. "We are delighted to welcome Dr. Andreas Grauer to our executive leadership team as Chief Medical Officer. Dr. Grauer has an extensive track record in leading clinical development

    4/20/26 7:00:00 AM ET
    $OMER
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts

    Adds dedicated business development leadership to support Tempest's strategic prioritiesWill lead China outreach and cross-border partnership effortsTo support ongoing partnering discussions for Phase 3-ready amezalpat program, including potential China development opportunities BRISBANE, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST) ("Tempest"), a clinical-stage biotechnology company developing a pipeline of advanced CAR-T cell therapy product candidates to treat cancer, today announced the appointment of Andrew Fang, Ph.D., as Head of Business Development. Dr. Fang will lead Tempest's global business development efforts, including strategic partners

    4/14/26 8:00:00 AM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rani Therapeutics Appoints Dr. Sara Kenkare-Mitra as Strategic Advisor to Advance Platform and Clinical Strategy

    SAN JOSE, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the appointment of Dr. Sara Kenkare-Mitra as a Strategic Advisor. Dr. Kenkare-Mitra brings nearly three decades of experience in biologics and small molecule drug discovery and development, with a proven track record of global regulatory approvals and commercial launches across oncology, immunology, neurodegeneration, ophthalmology, and respiratory diseases. "Sara is a highly accomplished leader and respected drug developer, and we are thrilled to we

    4/9/26 7:00:00 AM ET
    $RANI
    Biotechnology: Pharmaceutical Preparations
    Health Care